Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

ABSTRACT Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of these antibodies as anticancer agents has been extensively studied, but the results of clinical trials were disappointing. The observed lack of anticancer activity could be attributed to intrinsic or acquired resistance of tumor cells to this type of treatment. A possible strategy to circumvent drug resistance would be to strike tumor cells with a second modality based on a different mechanism of action. We therefore set out to generate and optimize a bispecific antibody targeting TRAIL-R2 and CD3. After the construction of different bispecific antibodies in tandem-scFv or single-chain diabody formats to reduce possible immunogenicity, we selected a humanized bispecific antibody with very low aggregates and long-term high stability and functionality. This antibody triggered TRAIL-R2 in an agonistic manner and its anticancer activity proved dramatically potentiated by the redirection of cytotoxic T cells against both sensitive and resistant melanoma cells. The results of our study show that combining the TRAIL-based antitumor strategy with an immunotherapeutic approach in a single molecule could be an effective addition to the anticancer armamentarium.

[1]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[2]  Ulrich Brinkmann,et al.  The making of bispecific antibodies , 2017, mAbs.

[3]  G C P van Zundert,et al.  The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. , 2016, Journal of molecular biology.

[4]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[5]  L. Buie,et al.  Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. , 2015, The Annals of pharmacotherapy.

[6]  G. Sethi,et al.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy , 2015, Experimental biology and medicine.

[7]  M. Sanford.  Blinatumomab: First Global Approval , 2015, Drugs.

[8]  U. Brinkmann,et al.  Bispecific antibodies. , 2015, Drug discovery today.

[9]  B. Aggarwal,et al.  Targeting death receptors for TRAIL by agents designed by Mother Nature. , 2014, Trends in pharmacological sciences.

[10]  S. Canevari,et al.  Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma , 2014, Cell Death and Disease.

[11]  A. Rosato,et al.  A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. , 2013, European journal of cancer.

[12]  S. Canevari,et al.  Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. , 2013, Future oncology.

[13]  Diana Gil,et al.  Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments , 2013, Advances in bioscience and biotechnology.

[14]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[15]  M. Manns,et al.  Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. , 2011, Journal of autoimmunity.

[16]  L. Diaz,et al.  Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.

[17]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Baeuerle,et al.  Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.

[19]  P. Moore,et al.  Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.

[20]  F. Stricher,et al.  Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants , 2010, Cell Death and Disease.

[21]  Robert Mabry,et al.  Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. , 2010, IDrugs : the investigational drugs journal.

[22]  P. Moore,et al.  Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.

[23]  R. Kontermann.  Alternative antibody formats. , 2010, Current opinion in molecular therapeutics.

[24]  C. la Vecchia,et al.  Elevated levels of the acute‐phase serum amyloid are associated with heightened lung cancer risk , 2010, Cancer.

[25]  W. Quax,et al.  Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. , 2009, Biochemistry.

[26]  A. Lugovskoy,et al.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .

[27]  Scott M Glaser,et al.  Antibody therapeutics, antibody engineering, and the merits of protein stability. , 2008, Current opinion in drug discovery & development.

[28]  Paolo Marcatili,et al.  PIGS: automatic prediction of antibody structures , 2008, Bioinform..

[29]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[30]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Lawrence,et al.  Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 , 2008, Cell Death and Differentiation.

[32]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[33]  P. Kufer,et al.  BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.

[34]  G. Screaton,et al.  Expression of TRAIL and TRAIL receptors in normal and malignant tissues , 2005, Cell Research.

[35]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[36]  K. Knutson,et al.  Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients , 2004, Journal of Clinical Immunology.

[37]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[38]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[39]  C. J. Hutchings,et al.  Generation of Naive Human Antibody Libraries , 2001 .

[40]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[41]  S. Canevari,et al.  Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.

[42]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[43]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[44]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[45]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[46]  H R Hoogenboom,et al.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.

[47]  A. Lanzavecchia,et al.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.

[48]  P. Capel,et al.  Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells , 1983, Nature.

[49]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .